title: [Effect of hesperidin on behavior and HPA axis of rat model of chronic stress-induced depression].
abstract: OBJECTIVE
  To observe the effect of hesperidin on behavior and hypothalamic-pituitary-adrenal (HPA) axis of ratmodel of chronic stress-induced depression.
  
  
  METHODS
  Chronic unpredictable mild stress (CUMS) was used to establish the rat depression model. Sixty male SD rats were divided randomly into six groups: the normal group, the model group, the hesperidin (40, 80, 160 mg x kg(-1)) group and the positive fluoxetine (10 mg x kg(-1)) group. They were orally administered with drugs for three weeks. The sucrose preference test and the forced swimming test (FST) were assayed to detect animal behavior. The levels of corticosterone (CORT) in serum, mRNA of corticotropin release factor (CRF) in hypothalamus as well as protein expression of glucocorticoid receptor (GR) in paraventricular nucleus (PVN) were determined to clarify the anti-depression effect and mechanism of hesperidin.
  
  
  RESULTS
  Compared with the model group, rats in the hesperidin (40, 80, 160 mg x kg(-1)) treatment group showed significant increase in the sucrose consumption and decrease in the immobility time in FST to varying degrees. Meanwhile, the excessively high serum CORT and adrenal index of CUMS rats were reversed by treatment with hesperidin. In addition, hesperidin inhibited CRF mRNA expression in hypothalamus and up-regulated GR protein expression in PVN among CUMS rats.
  
  
  CONCLUSIONS
  Hesperidin could effectively improve the behavior of CUMS rats and show the anti-depression effect. Its mechanisms may be related to the function of regulating HPA axis.
authors.affiliation: Department of Pathology, Anhui Medical University, Hefei 230032, China. sdcaili@163.com
authors.forename: Li
authors.initials: L
authors.lastname: Cai
authors.forename: Rong
authors.initials: R
authors.lastname: Li
authors.forename: Qing-Qing
authors.initials: QQ
authors.lastname: Wu
authors.forename: Ting-Ni
authors.initials: TN
authors.lastname: Wu
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D003345:Corticosterone / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000235:genetics / Q000378:metabolism; D003863:Depression / Q000188:drug therapy* / Q000209:etiology; D005473:Fluoxetine / Q000008:administration & dosage; D005786:Gene Expression Regulation / Q000187:drug effects; D006569:Hesperidin / Q000008:administration & dosage / Q000494:pharmacology*; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000503:physiopathology; D007031:Hypothalamus / Q000378:metabolism; D008297:Male; D023421:Models, Animal; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000503:physiopathology; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D011965:Receptors, Glucocorticoid / Q000378:metabolism; D013315:Stress, Psychological / Q000150:complications / Q000188:drug therapy*; D013395:Sucrose / Q000378:metabolism; D013550:Swimming; D015854:Up-Regulation
chemical_list: D011965:Receptors, Glucocorticoid; D005473:Fluoxetine; D013395:Sucrose; D003346:Corticotropin-Releasing Hormone; D006569:Hesperidin; D003345:Corticosterone